Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 14/20 | 0.55 |
| ▸ | MERTK | Q12866 | 1/20 | 0.54 |
| ▸ | MET | P08581 | 6/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.52 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30066135 | 1.00 | AXL (0.55) | AXLMERTKMETKDRPDGFRA | |
| SCHEMBL21083204 | 0.90 | KDR (0.57) | AXLMERTKMETKDRPDGFRA | |
| SCHEMBL1132195 | 0.90 | AXL (0.62) | AXLMERTKMETKDRPDGFRA | |
| SCHEMBL29487165 | 0.90 | AXL (0.60) | AXLMERTKMETKDRPDGFRA | |
| SCHEMBL1132601 | 0.90 | AXL (0.60) | AXLMERTKMETKDRPDGFRA | |
| SCHEMBL22960013 | 0.88 | AXL (0.51) | AXLMERTKMETKDRPDGFRA | |
| SCHEMBL29487144 | 0.88 | AXL (0.51) | AXLMERTKMETKDRPDGFRA | |
| SCHEMBL7238249 | 0.87 | MET (0.55) | AXLMERTKMETKDRPDGFRA | |
| SCHEMBL21201049 | 0.87 | MET (0.54) | AXLMERTKMETKDRPDGFRA | |
| SCHEMBL1132608 | 0.87 | AXL (0.53) | AXLMERTKMETKDRPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230107889-A1 | PROCESS FOR PRODUCING ACYLTHIOUREA COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-04-06 | — | — | US | claimed |
| EP-4105200-A1 | METHOD FOR PRODUCING ACYLTHIOUREA COMPOUND | Taiho Pharmaceutical Co., Ltd. (JP) | 2022-12-21 | — | — | EP | claimed |
| WO-2021162096-A1 | METHOD FOR PRODUCING ACYLTHIOUREA COMPOUND | 大鵬薬品工業株式会社 | 2021-08-19 | — | — | WO | claimed |
| EP-4552695-A2 | TYROSINE KINASES INHIBITORS AND USES THEREOF | Great Novel Therapeutics Biotech & Medicals Corporation (TW) | 2025-05-14 | — | — | EP | disclosed |
| CN-119841776-A | Tyrosine kinase inhibitors and uses thereof | 华上生技医药股份有限公司 | 2025-04-18 | — | — | CN | disclosed |
| US-20250120967-A1 | TYROSINE KINASES INHIBITORS AND USES THEREOF | Great Novel Therapeutics Biotech & Medicals Corporation (TW) | 2025-04-17 | — | — | US | disclosed |
| US-20230107889-A1 | PROCESS FOR PRODUCING ACYLTHIOUREA COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-04-06 | — | — | US | disclosed |
| US-20230107889-A1 | PROCESS FOR PRODUCING ACYLTHIOUREA COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-04-06 | — | — | US | disclosed |
| EP-4105200-A1 | METHOD FOR PRODUCING ACYLTHIOUREA COMPOUND | Taiho Pharmaceutical Co., Ltd. (JP) | 2022-12-21 | — | — | EP | disclosed |
| US-20220235064-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO., LTD. (KR) | 2022-07-28 | — | — | US | disclosed |
| EP-4011885-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Wellmarker Bio Co., Ltd. (KR) | 2022-06-15 | — | — | EP | disclosed |
| WO-2021162097-A1 | ANALOGOUS SUBSTANCES OF ACYL THIOUREA COMPOUND | 大鵬薬品工業株式会社 | 2021-08-19 | — | — | WO | disclosed |
| WO-2021025407-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 웰마커바이오 주식회사 | 2021-02-11 | — | — | WO | disclosed |
| WO-2021025407-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 웰마커바이오 주식회사 | 2021-02-11 | — | — | WO | disclosed |
| US-20130225581-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD (JP) | 2013-08-29 | — | — | US | disclosed |
| EP-2287155-B1 | ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2013-07-17 | — | — | EP | disclosed |
| EP-2594566-A1 | NITROGENATED AROMATIC HETEROCYCLIC RING DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-8304427-B2 | Acylthiourea compound or salt thereof, and use thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-11-06 | — | — | US | disclosed |
| EP-2287155-A1 | ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE OF THE COMPOUND OR THE SALT | Taiho Pharmaceutical Co., Ltd. (JP) | 2011-02-23 | — | — | EP | disclosed |
| US-20110034439-A1 | ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034439-A1 | ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE THEREOF | MET, HGF, STAT6 | AXL 568/4885MERTK 150/4885MET 1/4885 |
| US-20250120967-A1 | TYROSINE KINASES INHIBITORS AND USES THEREOF | LCK, LTK, HIF1AN | AXL 339/4885MERTK 26/4885MET 592/4885 |
| US-20220235064-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ROS1, ROR1, RET | AXL 377/4885MERTK 518/4885MET 63/4885 |
| US-20230107889-A1 | PROCESS FOR PRODUCING ACYLTHIOUREA COMPOUND | AGPAT2, ACAT2, AADAC | AXL 4077/4885MERTK 3422/4885MET 2207/4885 |
| US-20130225581-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC DERIVATIVE | FGFR3, FGFR1, FGFR4 | AXL 21/4885MERTK 408/4885MET 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.